选择语言
免费注册积分兑换
关注公众号
我的购物车
收藏产品

HEK293/Human LRRC15 Stable Cell Line

COAMS
DS
用户评价
货号-规格
价格
Qty.
合计0件 产品金额0
0
加入购物车
新品建议
增项建议

产品详情

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required

  • 描述（Description）

    The HEK293/Human LRRC15 Stable Cell Line was engineered to express the receptor full length human LRRC15 (Gene ID: 131578), used to mimic cancer target cells. Surface expression of human LRRC15 was confirmed by flow cytometry.

  • 应用说明（Application）

    • Useful for cell-based LRRC15 binding assay

  • 生长特性（Growth Properties）

    Adherent

  • 筛选标记（Selection Marker）

    Puromycin (2 μg/mL)

  • 培养基（Complete Growth Medium）

    DMEM + 10% FBS

  • 冻存液（Freeze Medium）

    Serum-free cell cryopreservation medium

  • 装量（Quantity）

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • 存储（Storage）

    Frozen in liquid nitrogen.

  • 支原体检测（Mycoplasma Testing）

    Negative

  • 无菌检测（Sterility Testing）

    Negative

  • 使用说明（Instructions for Use）

    See data sheet for detailed culturing and assay protocol.

产品展示

  • Receptor Assay

    LRRC15 FACS

    Expression analysis of human LRRC15 on HEK293/Human LRRC15 Stable Cell Line by FACS.
    Cell surface staining was performed on HEK293/Human LRRC15 Stable Cell Line or negative control cell using anti-human LRRC15 antibody followed by staining with FITC anti-mouse IgG antibody.

    Protocol
*如有相关细胞池需求请联系我们

用户评价
发表评论

背景介绍

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

前沿进展

 
药物研发进展
  • 英文全称：

    Leucine-rich repeat-containing protein 15

  • 中文全称：

    富含亮氨酸重复序列蛋白-15

  • 种类：

  • 上市药物数量：

    0 详情

  • 临床药物数量：

    0 详情

  • 最高研发阶段：

    临床前

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍